Lipid clinic experience with bempedoic acid in three UK centres

References

• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx144.
   PubMed Web of Science ®Google Scholar
• Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9–e119. doi:10.1161/CIR.0000000000001168.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline [NG238]. London, UK: National Institute for Health and Care Excellence; 2023.
   Google Scholar
• Ballantyne CM, Bays H, Catapano AL, et al. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;35(4):853–864. doi:10.1007/s10557-021-07147-5.
   PubMed Web of Science ®Google Scholar
• Drexel H, Mader A. Bempedoic acid – How will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use. Cardiology. 2023;149(1):71–77. doi:10.1159/000535372.
   PubMed Web of Science ®Google Scholar
• Masana Marín L, Plana Gil N. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clin Investig Arterioscler. 2021;33(Suppl 1):53–57. doi:10.1016/j.arteri.2021.02.012.
   PubMedGoogle Scholar
• Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–1364. doi:10.1056/NEJMoa2215024.
   PubMed Web of Science ®Google Scholar
• Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the international lipid expert panel (ILEP). Prog Cardiovasc Dis. 2023;79:2–11. doi:10.1016/j.pcad.2023.03.001.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of Non-Statin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785–1822. doi:10.1016/j.jacc.2017.07.745.
   PubMed Web of Science ®Google Scholar
• Tan YY, Papez V, Chang WH, et al. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674–e89. doi:10.1016/S2666-7568(22)00186-6.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. London UK: national Institute for Health and Care Excellence; 2021.
   Google Scholar
• Wierzbicki AS, Grant P. Drugs for hypercholesterolaemia – from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Clin Med. 2016;16(4):353–357. doi:10.7861/clinmedicine.16-4-353.
   PubMed Web of Science ®Google Scholar
• Sampson M, Ling C, Sun Q, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540–548. doi:10.1001/jamacardio.2020.0013.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Viljoen A, Viljoen S, et al. Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. Int J Clin Pract. 2018;72(9):e13242. doi:10.1111/ijcp.13242.
   PubMed Web of Science ®Google Scholar
• Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–3223. doi:10.1093/eurheartj/ehac015.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366–1418. doi:10.1016/j.jacc.2022.07.006.
   PubMed Web of Science ®Google Scholar
• Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649–659 e6. doi:10.1016/j.jacl.2020.08.009.
   PubMed Web of Science ®Google Scholar
• De Filippo O, D’Ascenzo F, Iannaccone M, et al. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol. 2023;22(1):324. doi:10.1186/s12933-023-02022-z.
   PubMed Web of Science ®Google Scholar
• Brautbar A, Barbalic M, Chen F, et al. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. J Lipid Res. 2013;54(7):1980–1987. doi:10.1194/jlr.M034132.
   PubMed Web of Science ®Google Scholar
• Bentanachs R, Velázquez AM, Sánchez RM, et al. Bempedoic acid as a PPARalpha activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. Clin Investig Arterioscler. 2022;34(2):57–67. doi:10.1016/j.artere.2022.03.001.
   PubMed Web of Science ®Google Scholar
• Warden BA, Cardiology BA, Purnell JQ, et al. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol. 2022;16(1):94–103. doi:10.1016/j.jacl.2021.11.013.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Koskinas K, Averna M, et al. Effectiveness and safety of bempedoic acid in routine clinical practice: 1-year follow-up snapshot of the MILOS German cohort. European Heart J. 2023;44(Supplement_2):810. doi:10.1093/eurheartj/ehad655.2810.
   Google Scholar
• Demeure F, Sperone A, Snel M, et al. Real-life experience of the first patients treated with bempedoic acid in 2 lipid clinics of Belgium. Atherosclerosis. 2023;379: S57–S58. doi:10.1016/j.atherosclerosis.2023.06.840.
   Web of Science ®Google Scholar
• Schumann F, Steinhagen-Thiessen E, Bobbert T, et al. New data of the treatment with bempedoic acid in clinical routine. Atherosclerosis. 2022;355:224. doi:10.1016/j.atherosclerosis.2022.06.877.
   Web of Science ®Google Scholar
• McCarron EP, Hamilton P, Roberts BV. Real world efficacy of bempedoic acid in statin-intolerant patients with high cardiovascular risk. Atherosclerosis. 2022;355:220. doi:10.1016/j.atherosclerosis.2022.06.863.
   Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Bays HE, et al. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from the CLEAR harmony Open-Label extension study). Am J Cardiol. 2022;174:1–11. doi:10.1016/j.amjcard.2022.03.020.
   PubMed Web of Science ®Google Scholar
• Chin YH, Lim O, Lin C, et al. Meta-analysis of the placebo and nocebo effects associated with placebo treatment in randomized trials of lipid-lowering therapies. Eur Heart J Qual Care Clin Outcomes. 2023;9(5):511–519. doi:10.1093/ehjqcco/qcac060.
   PubMed Web of Science ®Google Scholar
• Luo X, Lv M, Zhang X, et al. Clinical manifestations of COVID-19: an overview of 102 systematic reviews with evidence mapping. J Evid Based Med. 2022;15(3):201–215. doi:10.1111/jebm.12483.
   PubMedGoogle Scholar